Biochemical markers in the follow-up of medullary thyroid cancer

Thyroid

Volumn 16, Issue 11, 2006, Pages 1163-1170

  De Groot, Jan Willem B ^a   Kema, Ido P ^a   Breukelman, Henk ^a   Van Der Veer, Eveline ^a   Wiggers, Theo ^a   Plukker, John T M ^a   Wolffenbuttel, Bruce H R ^a   Links, Thera P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ADRENALIN; BIOCHEMICAL MARKER; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CATECHOLAMINE; CHROMOGRANIN A; DOPAMINE; HISTAMINE; HOMOVANILLIC ACID; METADRENALIN; METHOXYTYRAMINE; NORADRENALIN; NORMETADRENALIN; NORMETADRENALIN 3; SEROTONIN; TRYPTASE; TYRAMINE; VANILMANDELIC ACID;

ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER STAGING; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE SYNTHESIS; CATECHOLAMINE URINE LEVEL; CELL LEVEL; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROTONIN BLOOD LEVEL; SEROTONIN METABOLISM; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; URINALYSIS; URINE LEVEL;

ADULT; AGED; BLOOD PLATELETS; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; CATECHOLAMINES; CHROMOGRANIN A; FEMALE; FOLLOW-UP STUDIES; HISTAMINE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PROSPECTIVE STUDIES; SEROTONIN; THYROID NEOPLASMS; TRYPTASES; TUMOR MARKERS, BIOLOGICAL;

EID: 33845261839     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.1163     Document Type: Article

References (41)

1. Engelbach M, Gorges R, Forst T, Pfutzner A, Dawood R, Heerdt S, Kunt T, Bockisch A, Beyer J 2000 Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab 85:1890-1894.
2. Orlandi F, Caraci P, Mussa A, Saggiorato E, Pancani G, Angeli A 2001 Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer 8:135-147.
3. Leboulleux S, Baudin E, Travagli JP, Schlumberger M 2004 Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61:299-310.
4. Day R, Salzet M 2002 The neuroendocrine phenotype, cellular plasticity, and the search for genetic switches: redefining the diffuse neuroendocrine system. Neuro Endocrinol Lett 23:447-451.
5. Barakat MT, Meeran K, Bloom SR 2004 Neuroendocrine tumours. Endocr Relat Cancer 11:1-18
6. Pearse AG 1968 Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimo-branchial C cells and calcitonin. Proc R Soc Lond B Biol Sci 170:71-80.
7. Pearse AG 1980 The APUD concept and hormone production. Clin Endocrinol Metab 9:211-222.
8. Lippman SM, Mendelsohn G, Trump DL, Wells SA, Jr., Baylin SB 1982 The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase. J Clin Endocrinol Metab 54:233-240.
9. Hanna FW, Ardill JE, Johnston CF, Cunningham RT, Curry WJ, Russell CF, Buchanan KD 1997 Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid. J Endocrinol 152:275-281.
10. Meijer WG, Copray SC, Hollema H, Kema IP, Zwart N, Mantingh-Otter I, Links TP, Willemse PH, de Vries EG 2003 Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. Clin Chem 49:586-593.
11. Oishi S, Sasaki M, Sato T, Hirota Y, Takahashi M 1986 Imaging and uptake mechanism of 131I-meta-iodobenzylguanidine in medullary thyroid carcinoma. Endocrinol Jpn 33:309-315.
12. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E 2001 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64-71.
13. Kema IP, de Vries EG, Slooff MJ, Biesma B, Muskiet FA 1994 Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clin Chem 40:86-95.
14. Kema IP, Schellings AM, Meiborg G, Hoppenbrouwers CJ, Muskiet FA 1992 Influence of a serotonin- and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites. Clin Chem 38:1730-1736.
15. Kema IP, Meiborg G, Nagel GT, Stob GJ, Muskiet FA 1993 Isotope dilution ammonia chemical ionization mass fragmentographic analysis of urinary 3-O-methylated catecholamine metabolites. Rapid sample clean-up by derivatization and extraction of lyophilized samples. J Chromatogr 617:181-189.
16. Muskiet FA, Fremouw-Ottevangers DC, Nagel GT, Wolthers BG 1979 Determination of 4-O-methylated catecholamine metabolites in urine by mass fragmentography. Clin Chem 25:1708-1713.
17. Kema IP, Schellings AM, Hoppenbrouwers CJ, Rutgers HM, de Vries EG, Muskiet FA 1993 High performance liquid chromatographic profiling of tryptophan and related indoles in body fluids and tissues of carcinoid patients. Clin Chim Acta 221:143-158.
18. Goldstein DS, Eisenhofer G, Kopin IJ 2003 Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 305:800-811.
19. Zabel M, Grzeszkowiak J 1997 Characterisation of thyroid medullary carcinoma TT cell line. Histol Histopathol 12:283-289.
20. Uribe M, Fenoglio-Preiser CM, Grimes M, Feind C 1985 Medullary carcinoma of the thyroid gland. Clinical, pathological, and immunohistochemical features with review of the literature. Am J Surg Pathol 9:577-594.
21. Harach HR, Bergholm U 1993 Medullary carcinoma of the thyroid with carcinoid-like features. J Clin Pathol 46:113-117.
22. Hocevar M, Bergant D, Auersperg M, Golouh R 2001 Medullary carcinoma of the thyroid with serotonin production and carcinoid-like syndrome. Eur J Surg Oncol 27:219-222.
23. Feldman JM, Farrell RE, Wells SA, Jr. 1979 Serotonin metabolism and platelet monoamine oxidase activity in patients with medullary carcinoma of the thyroid and pheochromocytoma. Am J Med Sci 278:39-48.
24. Engbaek F 1985 Serotonin (5-hydroxytryptamine) in medullary thyroid carcinoma with or without pheochromocytoma. Eur J Cancer Clin Oncol 21:469-473.
25. Meijer WG, Kema IP, Volmer M, Willemse PH, de Vries EG 2000 Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 46:1588-1596.
26. Russo AF, Clark MS, Durham PL 1996 Thyroid parafollicular cells. An accessible model for the study of serotonergic neurons. Mol Neurobiol 13:257-276.
27. Tamir H, Liu KP, Hsiung SC, Adlersberg M, Nunez EA, Gershon MD 1990 Multiple signal transduction mechanisms leading to the secretion of 5-hydroxytryptamine by MTC cells, a neurectodermally derived cell line. J Neurosci 10:3743-3753.
28. Matsuki Y, Tanimoto A, Hamada T, Sasaguri Y 2003 Histidine decarboxylase expression as a new sensitive and specific marker for small cell lung carcinoma. Mod Pathol 16:72-78.
29. Wymenga AN, de Monchy JG, de Vries EG 1995 The carcinoid syndrome and angioedema. Ann Intern Med 123:636.
30. van der Horst-Schrivers AN, Wymenga AN, Links TP, Willemse PH, Kema IP, de Vries EG 2004 Complications of midgut carcinoid tumors and carcinoid syndrome. Neuroendocrinology 80 Suppl 1:28-32.
31. Tucker LE, O'Neal LW, Martin SA 1984 Pseudocarcinoid syndrome due to medullary carcinoma of the thyroid. Mo Med 81:607-608,620.
32. Keeling CA, Basso LV 1988 Iodine-131 MIBG uptake in metastatic medullary carcinoma of the thyroid. A patient treated with somatostatin. Clin Nucl Med 13:260-263.
33. Pacak K, Eisenhofer G, Goldstein DS 2004 Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 25:568-580.
34. de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT 2004 Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11:786-794.
35. O'Connor DT, Deftos LJ 1986 Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 314:1145-1151.
36. Blind E, Schmidt-Gayk H, Sinn HP, O'Connor DT, Raue F 1992 Chromogranin A as tumor marker in medullary thyroid carcinoma. Thyroid 2:5-10.
37. Franke WG, Pinkert J, Runge R, Bredow J, Wunderlich G, Koch R 2000 Chromogranin A: an additional tumor marker for postoperative recurrence and metastases of medullary thyroid carcinomas? Anticancer Res 20:5257-5260.
38. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E 1984 Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 53:278-285.
39. Saad MF, Fritsche HA, Jr., Samaan NA 1984 Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 58:889-894.
40. Pacini F, DeGroot LJ 2004 Thyroid neoplasia. www.thyroid manager.org. 02-06-2006.
41. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts SW 1997Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82:2622-2628.